Carboxypeptidase U (TAFIa) prevents lysis from proceeding into the propagation phase through a threshold-dependent mechanism

Journal of Thrombosis and Haemostasis

Volumn 2, Issue 3, 2004, Pages 416-423

  Leurs, J ^a   Nerme, V ^b   Sim, Y ^a   Hendriks, Dirk ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

Carboxypeptidase U; Clot lysis; TAFI; Thrombin inhibitor; Thrombomodulin

Indexed keywords

BLOOD CLOTTING FACTOR; FIBRIN; PLASMIN; PLASMINOGEN; THROMBIN; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; THROMBIN INHIBITOR; THROMBOMODULIN; TISSUE PLASMINOGEN ACTIVATOR; RECOMBINANT PROTEIN;

ARTICLE; BLOOD CLOT LYSIS; BLOOD CLOTTING TIME; CONTROLLED STUDY; DISSOLUTION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME STABILITY; FIBRINOLYSIS; HUMAN; HUMAN EXPERIMENT; IN VITRO STUDY; NORMAL HUMAN; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; BIOLOGICAL MODEL; HEMOLYSIS; KINETICS; METABOLISM; PHOTOMETRY; PHYSIOLOGY; REFERENCE VALUE;

CARBOXYPEPTIDASE U; HEMOLYSIS; HUMANS; KINETICS; MODELS, BIOLOGICAL; NEPHELOMETRY AND TURBIDIMETRY; RECOMBINANT PROTEINS; REFERENCE VALUES; THROMBIN; THROMBOMODULIN; TISSUE PLASMINOGEN ACTIVATOR;

EID: 3142584783     PISSN: 15387933     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2004.00605.x     Document Type: Article

References (24)

1. Fleury V, Angles-Cano E. Characterization of the binding of plasminogen to fibrin surfaces: the role of carboxy-terminal lysines. Biochemistry 1991; 30: 7630-8.
2. Wang W, Boffa MB, Bajzar L, Walker JB, Nesheim ME. A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activable fibrinolysis inhibitor. J Biol Chem 1998; 273 27176-81.
3. Sakharov DV, Plow EF, Rijken DC. On the mechanism of the antifibrinolytic activity of plasma carboxypeptidase B. J Biol Chem 1997; 272: 14477-82.
4. Mao SS, Cooper CM, Wood T, Shafer JA, Gardell SJ. Characterization of plasmin-mediated activation of plasma procarboxypeptidase B. Modulation by glycosaminoglycans. J Biol Chem 1999; 274: 35046-52.
5. Bajzar L, Manuel R, Nesheim ME. Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor. J Biol Chem 1995; 270: 14477-84.
6. Eaton DL, Malloy BE, Tsai SP, Henzel W, Drayna D. Isolation, molecular cloning, and partial characterization of a novel carboxypeptidase B from human plasma. J Biol Chem 1991; 266: 21833-8.
7. Schatteman K, Goossens F, Scharpe S, Hendriks D. Proteolytic activation of purified human procarboxypeptidase U. Clinica Chimica Acta 2000; 292: 25-40.
8. Bajzar L, Morser J, Nesheim M. TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex. J Biol Chem 1996; 271: 16603-8.
9. Campbell W, Yonezu K, Shinohara T, Okada H. An arginine carboxypeptidase generated during coagulation is diminished or absent in patients with rheumatoid arthritis. J Lab Clin Med 1990; 115: 610-2.
10. Hendriks D, Wang W, Scharpe S, Lommaert MP, van Sande M. Purification and characterization of a new arginine carboxypeptidase in human serum. Biochim Biophys Acta 1990; 1034: 86-92.
11. Marx PF, Hackeng TM, Dawson PE, Griffin JH, Meijers JC, Bouma BN. Inactivation of active thrombin-activable fibrinolysis inhibitor takes place by a process that involves conformational instability rather than proteolytic cleavage. J Biol Chem 2000; 275: 12410-5.
12. Boffa MB, Bell R, Stevens WK, Nesheim ME. Roles of thermal instability and proteolytic cleavage in regulation of activated thrombin-activable fibrinolysis inhibitor. J Biol Chem 2000; 275 12868-78.
13. Schneider M, Boffa M, Stewart R, Rahman M, Koschinsky M, Nesheim M. Two naturally occurring variants of TAFI (Thr-325 and Ile-325) differ substantially with respect to thermal stability and antifibrinolytic activity of the enzyme. J Biol Chem 2002; 277 1021-30.
14. Leurs J, Wissing BM, Nerme V, Schatteman K, Björquist P, Hendriks D. Different mechanisms contribute to the biphasic pattern of carboxypeptidase U (TAFIa) generation during in vitro clot lysis in human plasma. Thromb Haemost 2003; 89: 264-71.
15. Stromqvist M, Schatteman K, Leurs J, Verkerk R, Andersson JO, Johansson T, Scharpé S, Hendriks D. Immunological assay for the determination of procarboxypeptidase U antigen levels in human plasma. Thromb Haemost 2001; 85: 12-7.
16. Teger-Nilsson AC, Bylund R, Gustafsson D, Gyzander E, Eriksson U. In vitro effects of inogatran, a selective low molecular weight thrombin inhibitor. Thromb Res 1997; 85: 133-45.
17. Wang W, Hendriks DF, Scharpe SS. Carboxypeptidase U, a plasma carboxypeptidase with high affinity for plasminogen. J Biol Chem 1994; 269: 15937-44.
18. Hendriks D, Scharpe S, van Sande M. Assay of carboxypeptidase N activity in serum by liquid-chromatographic determination of hippuric acid. Clin Chem 1985; 31: 1936-9.
19. Schatteman KA, Goossens FJ, Scharpe SS, Neels HM, Hendriks DF. Assay of procarboxypeptidase U, a novel determinant of the fibrinolytic cascade, in human plasma. Clin Chem 1999; 45: 807-13.
20. Wu C, Dong N, Da Cunha V, Martin-McNulty B, Tran K, Nagashima M, Wu Q, Morser J, Wang YX. Activated thrombin-activatable fibrinolysis inhibitor attenuates spontaneous fibrinolysis of batroxobin-induced fibrin deposition in rat lungs. Thromb Haemost 2003; 90: 414-21.
21. Hosaka Y, Takahashi Y, Ishii H. Thrombomodulin in human plasma contributes to inhibit fibrinolysis through acceleration of thrombin-dependent activation of plasma procarboxypeptidase B. Thromb Haemost 1998; 79: 371-7.
22. Mosnier LO, Meijers JC, Bouma BN. Regulation of fibrinolysis in plasma by TAFI and protein C is dependent on the concentration of thrombomodulin. Thromb Haemost 2001; 85: 5-11.
23. Deinum J, Elg S. The effect of melagatran on the binding of thrombin to antithrombin studied by plasmon resonance. Thromb Haemost 2000; 30 (Suppl. 1): 165.
24. Colucci M, D'Aprile AM, Italia A, Gresele P, Morser J, Semeraro N. Thrombin activatable fibrinolysis inhibitor (TAFI) does not inhibit in vitro thrombolysis by pharmacological concentrations of t-PA. Thromb Haemost 2001; 85: 661-6.